X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs PFIZER - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS PFIZER NOVARTIS/
PFIZER
 
P/E (TTM) x 321.8 34.3 936.8% View Chart
P/BV x 35.7 5.1 705.9% View Chart
Dividend Yield % 1.3 0.7 190.0%  

Financials

 NOVARTIS   PFIZER
EQUITY SHARE DATA
    NOVARTIS
Mar-18
PFIZER
Mar-18
NOVARTIS/
PFIZER
5-Yr Chart
Click to enlarge
High Rs7582,365 32.1%   
Low Rs5791,625 35.6%   
Sales per share (Unadj.) Rs228.4430.3 53.1%  
Earnings per share (Unadj.) Rs31.778.7 40.3%  
Cash flow per share (Unadj.) Rs32.893.2 35.2%  
Dividends per share (Unadj.) Rs10.0020.00 50.0%  
Dividend yield (eoy) %1.51.0 149.2%  
Book value per share (Unadj.) Rs297.1586.5 50.7%  
Shares outstanding (eoy) m24.6945.75 54.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.94.6 63.1%   
Avg P/E ratio x21.125.3 83.1%  
P/CF ratio (eoy) x20.421.4 95.3%  
Price / Book Value ratio x2.23.4 66.1%  
Dividend payout %31.525.4 124.0%   
Avg Mkt Cap Rs m16,50591,271 18.1%   
No. of employees `0000.72.6 25.4%   
Total wages/salary Rs m1,4453,143 46.0%   
Avg. sales/employee Rs Th8,441.37,484.8 112.8%   
Avg. wages/employee Rs Th2,163.61,195.0 181.1%   
Avg. net profit/employee Rs Th1,173.11,369.1 85.7%   
INCOME DATA
Net Sales Rs m5,63919,685 28.6%  
Other income Rs m1,7181,143 150.3%   
Total revenues Rs m7,35720,828 35.3%   
Gross profit Rs m-635,003 -1.2%  
Depreciation Rs m25663 3.8%   
Interest Rs m554 1,316.7%   
Profit before tax Rs m1,5755,479 28.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7921,878 42.1%   
Profit after tax Rs m7843,601 21.8%  
Gross profit margin %-1.125.4 -4.4%  
Effective tax rate %50.334.3 146.6%   
Net profit margin %13.918.3 76.0%  
BALANCE SHEET DATA
Current assets Rs m9,52224,167 39.4%   
Current liabilities Rs m3,2969,544 34.5%   
Net working cap to sales %110.474.3 148.6%  
Current ratio x2.92.5 114.1%  
Inventory Days Days3755 66.5%  
Debtors Days Days2829 99.0%  
Net fixed assets Rs m469,514 0.5%   
Share capital Rs m123458 27.0%   
"Free" reserves Rs m7,21326,375 27.3%   
Net worth Rs m7,33626,832 27.3%   
Long term debt Rs m025 0.0%   
Total assets Rs m11,10536,900 30.1%  
Interest coverage x29.51,305.5 2.3%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.5 95.2%   
Return on assets %7.69.8 77.3%  
Return on equity %10.713.4 79.6%  
Return on capital %22.220.4 108.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6122 270.5%   
Fx outflow Rs m3,6301,489 243.9%   
Net fx Rs m-3,570-1,466 243.4%   
CASH FLOW
From Operations Rs m1,6103,318 48.5%  
From Investments Rs m687-2,383 -28.8%  
From Financial Activity Rs m-2,677-1,104 242.5%  
Net Cashflow Rs m-380-169 225.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 63.9 117.4%  
Indian inst/Mut Fund % 2.0 7.5 26.7%  
FIIs % 1.6 4.9 32.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 23.7 90.7%  
Shareholders   41,647 85,207 48.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   WOCKHARDT LTD.  J.B.CHEMICALS  ORCHID PHARMA LTD  DIVIS LABORATORIES  FULFORD INDIA  

Compare NOVARTIS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Healthcare and Power Stocks Witness Buying(Closing)

Indian share markets continued to trade on a flat during closing hours of trade and ended the day marginally higher to close at fresh record high levels.

Related Views on News

PFIZER Announces Quarterly Results (1QFY19); Net Profit Up 60.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, PFIZER has posted a net profit of Rs 918 m (up 60.6% YoY). Sales on the other hand came in at Rs 5 bn (up 18.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 21, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS